ChIP-seq of PDAC tissues grown as patient-derived tumor xenografts
收藏官方服务：
资源简介：
ChIP-seq of PDAC tissues grown as patient-derived tumor xenografts
应用场景：
创建时间：
2018-05-29
相关数据集
CFL1-induced super enhancer RNA m6A modification promotes local chromatin accessibility and oncogenes transcription in pancreatic cancer [ATAC-seq]
Herein, we describe the landscape of m6A on super enhancer RNAs (seRNAs) in pancreatic ductal adenocarcinoma (PDAC) and demonstrate a regulatory axis involving m6A-seRNAs, H3K4me3 modification, chroma
NIAID Data Ecosystem60
EVI1 activates tumor-promoting transcriptional enhancers in pancreatic cancer [ATAC-seq].
Cancer cells utilize epigenetic alterations to acquire autonomous capabilities for tumor maintenance. Here, we show that pancreatic ductal adenocarcinoma (PDA) cells hijack super-enhancers (SEs) to ac
NIAID Data Ecosystem30
Altered Hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways [RNA-seq]
Transcriptional deregulation of oncogenic pathways is a hallmark of cancer, and can be due to epigenetic alterations. 5-hydroxymethylcytosine is a recently discovered epigenetic modification that has
NIAID Data Ecosystem10
Development of LHX6-inducible system in PK-1 and PK-9 cells. Development of LHX6-inducible system in PK-1 and PK-9 cells
Epigenetic gene silencing by aberrant DNA methylation leads to loss of key cellular pathways in tumorigenesis. DNA methylation-mediated silenced genes in pancreatic cancer were searched by methyl-CpG
NIAID Data Ecosystem40
PGRN-RIKEN-CALGB 80303 - Genome-wide Pharmacogenomic Study of Gemcitabine and Bevacizumab in Advanced Pancreatic Cancer. PGRN-RIKEN-CALGB 80303 - Genome-wide Pharmacogenomic Study of Gemcitabine and Bevacizumab in Advanced Pancreatic Cancer
CALGB 80303 was a randomized, phase III study in advanced pancreatic cancer patients treated with Gemcitabine plus either Bevacizumab or placebo. No difference in overall survival (OS) was observed be
NIAID Data Ecosystem20
